The results of the first safety and tolerability study based on such system have been recently published[187,190], demonstrating that surgical implantation and removal of devices containing NGF-secreting cells in the basal forebrain of AD patients are feasible, well tolerated and relatively safe, and that they do not generate NGF-related adverse events[190]. The gene discussed is NGF; the disease is Alzheimer disease.